

# Monaco

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0 (-)	0 (-)
Mortality (HIV+TB only)	0 (-)	0 (-)
Incidence (includes HIV+TB)	0 (-)	0 (-)
Incidence (HIV+TB only)		
Incidence (MDR/RR-TB)**	0 (0-0)	0 (0-0)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0 (0-0)	0 (0-0)	0 (0-0)
Males	0 (0-0)	0 (0-0)	0 (0-0)
Total	0 (0-0)	0 (0-0)	0 (-)

TB case notifications, 2015	
Total cases notified	0
Total new and relapse	0
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	
- % bacteriologically confirmed among pulmonary	

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	null

TB/HIV care in new and relapse TB patients, 2015	Number	(%)
Patients with known HIV-status who are HIV-positive	0	
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0-0)
Estimated % of TB cases with MDR/RR-TB	2.3% (1.4-3.2)	15% (13-18)	
% notified tested for rifampicin resistance			0
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014		0
Previously treated cases registered in 2014		0
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013	100%	3

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed



## Tuberculosis profile



— Mortality (excludes HIV+TB)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB